Development, Characterization, and Application of Monoclonal Antibodies against Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein | Zendy

Dipankar Das | Zendy; Sriram Kammila | Zendy; Mavanur R. Suresh | Zendy

Open Access

Development, Characterization, and Application of Monoclonal Antibodies against Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein

Author(s) -

Dipankar Das,

Sriram Kammila,

Mavanur R. Suresh

Publication year - 2010

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00293-10

Subject(s) - monoclonal antibody , virology , covid-19 , coronavirus , respiratory system , antibody , betacoronavirus , medicine , severe acute respiratory syndrome , monoclonal , immunology , pathology , outbreak , disease , infectious disease (medical specialty)

Five monoclonal antibodies (MAbs) against recombinant nucleocapsid protein (NP) of severe acute respiratory syndrome (SARS)-causing coronavirus (CoV) were developed by hybridoma technology. Epitope mapping by Western blotting showed that these anti-SARS-CoV NP MAbs bind to distinct domains of NP. These anti-SARS-CoV NP MAbs, with their high specificity, are potentially ideal candidates for developing early and sensitive diagnostic assays for SARS-CoV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research